CSWYF OTC
China Shineway Pharmaceutical Group Limited
1W: +0.0%
1M: -6.9%
3M: -12.7%
YTD: -12.7%
1Y: -12.7%
3Y: +16.9%
5Y: +3.9%
$1.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$3.8B
-16.4% ▼
5Y CAGR: +57.2%
Gross Profit
$2.8B
-16.6% ▼
5Y CAGR: +57.9%
Operating Income
$843M
-13.6% ▼
5Y CAGR: +65.1%
Net Income
$840M
+512.5% ▲
5Y CAGR: +62.9%
EPS (Diluted)
$1.11
+516.7% ▲
5Y CAGR: +63.9%
EBITDA
$1.2B
-2.5% ▼
5Y CAGR: +74.0%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $385M | $498M | $588M | $4.5B | $3.8B |
| YoY Growth | -2.3% | +29.4% | +18.0% | +668.0% | -16.4% |
| Cost of Revenue | $97M | $126M | $151M | $1.1B | $946M |
| Gross Profit | $288M | $373M | $437M | $3.4B | $2.8B |
| Gross Margin | 74.9% | 74.8% | 74.4% | 75.1% | 75.0% |
| R&D Expenses | $14M | $17M | $17M | $110M | $101M |
| SG&A Expenses | $1.5B | $1.8B | $2.1B | $2.3B | $1.9B |
| Operating Expenses | $227M | $290M | $331M | $2.4B | $2.0B |
| Operating Income | $61M | $83M | $106M | $976M | $843M |
| Operating Margin | 15.9% | 16.6% | 18.1% | 21.6% | 22.3% |
| Interest Expense | $2M | $194K | $94K | $3M | $6M |
| Income Before Tax | $57M | $111M | $137M | $175M | $1.1B |
| Tax Expense | $14M | $25M | $29M | $38M | $306M |
| Net Income | $43M | $86M | $108M | $137M | $840M |
| Net Margin | 11.1% | 17.3% | 18.3% | 3.0% | 22.2% |
| EPS (Diluted) | $0.06 | $0.11 | $0.14 | $0.18 | $1.11 |
| EBITDA | $67M | $121M | $145M | $1.3B | $1.2B |
| Shares Outstanding | 757M | 755M | 755M | 755M | 755M |